Peter Maple

Dr. Peter Maple

Research Group in Clinical Neurology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, NG7 2UH, UK
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1989 in The Lancet
Verified
Journal Article
Closed access
Peter MaplePeter Maple
Peter Maple
JHJ.M.T. Hamilton-Miller
J.M.T. Hamilton-Miller
WBW. Brumfitt
W. Brumfitt

15 August 2007 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
PCPhillippa Cumberland
Phillippa Cumberland
CSCaroline E. Shulman
Caroline E. Shulman
Peter MaplePeter Maple
Peter Maple
JBJudith N. Bulmer
Judith N. Bulmer
EDEdgar K. Dorman
Edgar K. Dorman
FCFelicity T. Cutts
Felicity T. Cutts
Background. In clinical trials, maternal tetanus toxoid (TT) vaccination is effective in protecting newborns against tetanus infection, but inadequate placental transfer of tetanus antibodies may contribute to lower-thanexpected rates of protection in routine practice. We studied the effect of placental malaria and maternal human immunodeficiency virus (HIV) infection on placental transfer of antibodies to tetanus.

27 September 2004 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
RPR. G. Pebody
R. G. Pebody
NGN. J. Gay
N. J. Gay
AGA. Giammanco
A. Giammanco
SBS. Baron
S. Baron
JSJ. Schellekens
J. Schellekens
EME. Miller
E. Miller
High titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in six Western European countries between 1994 and 1998 and related to historical surveillance and vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and acellular pertussis vaccine trials. For the serological surveys, high-titre sera (>125 units/ml) were distributed throughout all age groups in both high- (>90%) and low-coverage (<90%) countries. High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their primary programme (Italy, 11·5%; Western Germany, 13·3%; France, 4·3%; Eastern Germany, 4·0%) compared to other countries (The Netherlands, 0·5%; Finland, 0%). Recent infection was significantly more likely in adolescents (10–19 years old) and adults in high-coverage countries (Finland, The Netherlands, France, East Germany), whereas infection was more likely in children (3–9 years old) than adolescents in low-coverage (<90%; Italy, West Germany, United Kingdom) countries. The impact and role of programmatic changes introduced after these surveys aimed at protecting infants from severe disease by accelerating the primary schedule or vaccinating older children and adolescents with booster doses can be evaluated with this approach.

1 August 2000 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
WEW. J. Edmunds
W. J. Edmunds
RPR. G. Pebody
R. G. Pebody
HAH. Aggerback
H. Aggerback
SBS. Baron
S. Baron
GBG. Berbers
G. Berbers
EME. Miller
E. Miller
Seven countries in Western Europe collected large, representative serum banks across the entire age range and tested them for diphtheria anti-toxin (sample size ranged from 2991 to 7715). Although a variety of assays were used, the results were all standardized to those of a reference laboratory and expressed in international units. The standardization process, and the availability of similar, large data sets allowed comparative analyses to be performed in which a high degree of confidence could be ascribed to observed epidemiological differences. The results showed that there were large differences in the proportion of adults with insufficient levels of protection amongst different countries. For instance, roughly 35% of 50- to 60-year-olds were found to be seronegative (titre [les ] 0·01 IU/ml) in Finland compared with 70–75% in the United Kingdom. Furthermore, the proportion of seronegative adults would be expected to increase in some countries, notably Italy and the western part of Germany. In those countries with vaccination of military recruits there was a marked sex-related difference in the proportion of seropositive individuals. All countries have high levels of infant vaccine coverage (> 90%) but the accelerated schedule in the United Kingdom appears to result in lower anti-toxin titres than elsewhere. In Sweden, booster doses are not offered until 10 years of age which results in large numbers of children with inadequate levels of protection. Although the United Kingdom and Sweden both have higher proportions of seronegative children than elsewhere the likelihood of a resurgence of diphtheria in these countries seems remote.

1 April 1995 in The Lancet
Verified
Journal Article
Closed access
Peter MaplePeter Maple
Peter Maple
AEA. Efstratiou
A. Efstratiou
RGR.C. George
R.C. George
NAN.J. Andrews
N.J. Andrews
DSD. Sesardic
D. Sesardic

1 December 2003 in Vaccine
Verified
Journal Article
Closed access
AGA Giammanco
A Giammanco
ACA Chiarini
A Chiarini
Peter MaplePeter Maple
Peter Maple
NAN Andrews
N Andrews
RPR Pebody
R Pebody
ERE Reizenstein
E Reizenstein